S-1: Cardio Diagnostics Holdings Files for Resale of 1.2 Million Shares Amidst Regulatory Changes

Cardio Diagnostics Holdings has filed a registration statement for the resale of over 1.2 million shares of common stock by selling stockholders, amidst evolving FDA regulations for laboratory developed tests.

Summary

• Cardio Diagnostics Holdings has filed a registration statement for the resale of 1,235,939 shares of common stock by selling stockholders.
• The shares include 561,793 shares sold in a private placement and 674,146 shares issuable upon exercise of warrants.
• The company will not receive any proceeds from the sale of these shares.
• The company is an emerging growth company and a smaller reporting company, which allows for reduced reporting requirements.
• The company's first test, Epi+Gen CHD, is a three-year symptomatic CHD risk assessment clinical blood test.
• Their second product, PrecisionCHD, is an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease.
• The company earned $950 in revenue in 2022 and $17,065 in 2023.
• The company has secured an Innovative Technology Contract from Vizient, Inc. and is implementing its heart attack risk assessment test with Family Medicine Specialists.
• The company has secured CPT PLA codes from the American Medical Association for both Epi+Gen CHD (0439U) and PrecisionCHD (0440U).
• The FDA has published a final rule amending the definition of an IVD device to include IVDs manufactured by a clinical laboratory, which may significantly impact the company's operations and results.
• The company's financial statements include a disclosure indicating that its current liquidity position raises substantial doubt about its ability to continue as a going concern.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While the company has innovative technology and has secured some key partnerships, it faces significant financial challenges, regulatory hurdles, and competition. The going concern warning and limited revenue generation are major concerns.

Positives

• The company has secured an Innovative Technology Contract from Vizient, Inc., the nation's largest provider-driven healthcare performance improvement company.
• Family Medicine Specialists is implementing the company's heart attack risk assessment test, Epi+Gen CHD, covering at least 1,200 patients.
• The company has an arrangement with one of India's leading healthcare and medical instrumentation companies to introduce its solutions in India.
• The company has secured CPT PLA codes from the American Medical Association for both Epi+Gen CHD and PrecisionCHD, which is a key step in securing payor coverage.

Negatives

• The company has a limited operating history and has not generated significant revenues.
• The company has incurred operating losses since its inception and may never achieve or maintain profitability.
• The company's financial statements include a disclosure indicating that its current liquidity position raises substantial doubt about its ability to continue as a going concern.
• The market for epigenetic tests is fairly new and unproven.
• The company relies on a limited number of suppliers, contract manufacturers, and logistics providers.
• The company's tests are currently performed by a single contract high complexity CLIA laboratory.
• The company may be unable to scale its operations successfully.
• The company may be unable to maintain its Nasdaq listing if it is unable to comply with the various listing requirements of Nasdaq.
• The company may have difficulty raising additional capital when and if needed.

Risks

• The company has a limited operating history that makes it impossible to reliably predict future growth and operating results.
• The company's current liquidity position raises substantial doubt about its ability to continue as a going concern.
• The company has an unproven business model and has not generated significant revenues.
• The market for epigenetic tests is fairly new and unproven.
• The company may be unable to obtain and maintain regulatory clearance or approval for its tests.
• The pricing of the company's products and services and reimbursement for medical tests may not be sufficient to achieve its financial goals.
• The company may be unable to successfully compete with other companies.
• The company may be unable to maintain its existing or future licenses, or manufacturing, supply and distribution agreements.
• The company may be unable to raise needed financing in the future on acceptable terms, if at all.
• The company may be unable to maintain its listing on The Nasdaq Stock Market.
• The company's operational and financial performance could be negatively impacted by the potential short and long-term impact of a re-emergence of COVID-19 variants or any other pandemic.
• The company may be subject to general litigation that may materially adversely affect it and its operations.
• The company's management expects to continue to devote substantial time to maintaining and improving the internal controls over financial reporting and the requirements of being a public company which may, among other things, strain its resources, divert managements attention and affect its ability to accurately report its financial results and prevent fraud.
• The company's license agreement with University of Iowa Research Foundation (UIRF) includes a non-exclusive license of technical information that potentially could grant unaffiliated third parties access to materials and information considered derivative work made by the company, which could be used by such licensees to develop competitive products.
• The company may be unable to obtain and maintain regulatory clearance or approval for its tests, and any related restrictions and limitations of any cleared or approved product could negatively impact its financial condition.
• The company's products may not receive adequate coverage and reimbursement from third-party payors.
• The price of the company's common stock is likely to be volatile.
• The company may not be able to maintain its Nasdaq listing.
• A significant number of shares of the company's common stock are subject to issuance upon exercise of outstanding warrants and options, which upon such exercise or conversion may result in dilution to its security holders.
• The company has never paid dividends on its common stock, and it does not anticipate paying any cash dividends on its common stock in the foreseeable future.
• Sales of a substantial number of shares of the company's common stock in the public market by its existing stockholders could cause its stock price to decline.

Future Outlook

The company expects losses to continue as a result of its ongoing activities to increase the adoption of its products, to gain market recognition and acceptance of its products, to expand its marketing channels, to prepare its newly-acquired laboratory for operation and otherwise position itself to grow its revenue opportunities.

Management Comments

• The company aspires to give every American adult insight into their unique risk for various cardiovascular diseases.
• The company aims to become one of the leading medical technology companies for enabling improved prevention, detection, treatment and management of cardiovascular disease and associated co-morbidities.
• The company is transforming the approach to cardiovascular medicine from reactive to proactive and hopes to accelerate the adoption of Precision Medicine for all.
• The company believes that incorporating its solutions into routine clinical practice in and prevention efforts can help alter the trajectory that nearly one in two Americans is expected to develop some form of cardiovascular disease by 2035.

Industry Context

The announcement comes amidst a growing market for cardiovascular diagnostic testing, driven by an aging population, the rise of chronic diseases, and a shift towards value-based care. The company's focus on epigenetics-based clinical tests positions it in a unique space within this market, but it also faces competition from established players and new entrants.

Comparison to Industry Standards

• The company's Epi+Gen CHD test demonstrated a 76% and 78% sensitivity for men and women, respectively, for three-year CHD risk, compared to the average sensitivity of 44% and 32% for men and women, respectively, for the Framingham Risk Score and the ASCVD Pooled Cohort Equation.
• The company's PrecisionCHD test demonstrated an overall average area under the curve, sensitivity, and specificity in three independent test cohorts for detecting coronary heart disease of 82%, 79%, and 76%, respectively, compared to the sensitivity of 58% for exercise ECG.
• The company's tests are categorized as laboratory-developed tests (LDTs), which have historically been subject to enforcement discretion by the FDA, but this is changing with the new FDA rule.
• The company's tests are unique in that they are based on an individual's objective genetic and epigenetic DNA biomarkers, which are dynamic and can change over time with intervention, unlike genetic biomarkers which are static.

Stakeholder Impact

• Shareholders may experience dilution due to the potential issuance of additional shares.
• Employees may be affected by the company's financial instability.
• Customers may be impacted by the company's ability to scale its operations and maintain its services.
• Suppliers may be affected by the company's financial instability and ability to pay for goods and services.
• Creditors may be at risk due to the company's going concern warning.

Next Steps

• The company will continue to focus its efforts on establishing relationships with larger organizations and channel partners to increase adoption of its solutions.
• The company will continue to build clinical and health economics evidence to pursue payor coverage.
• The company will continue to evaluate an FDA regulatory pathway to enable broader access to its tests.
• The company will continue to develop additional products, including clinical tests for stroke, congestive heart failure and diabetes.

Key Dates

Keywords

Cardio Diagnostics, epigenetic tests, coronary heart disease, CHD, risk assessment, laboratory developed tests, FDA, medical technology, precision medicine, cardiovascular disease, stock resale, warrants, private placement, CLIA laboratory, CPT PLA codes